Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial

Resource type
Journal Article
Authors/contributors
Title
Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial
Publication
The Lancet
Date
2022-11-25
Volume
0
Issue
0
Journal Abbr
The Lancet
Accessed
11/27/22, 5:14 PM
ISSN
0140-6736, 1474-547X
Short Title
Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE)
Language
English
Library Catalog
Extra
Publisher: Elsevier
Citation
Thompson, G. R., Soriano, A., Cornely, O. A., Kullberg, B. J., Kollef, M., Vazquez, J., Honore, P. M., Bassetti, M., Pullman, J., Chayakulkeeree, M., Poromanski, I., Dignani, C., Das, A. F., Sandison, T., Pappas, P. G., Akova, M., AlAgha, R., Alangaden, G., Albrecht, S. J., … Zhang, Y. (2022). Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(22)02324-8
ORGANISMS
DRUGS AND THERAPIES
ATC 2023 Top Papers in TID
Link to this record